Physostigmine-induced myoclonus in Alzheimer’s disease

Richard Mayeux; Marilyn Albert; Michael Jenike

doi:10.1212/wnl.37.2.345

Physostigmine-induced myoclonus in Alzheimer’s disease

Richard Mayeux, Marilyn Albert, Michael Jenike

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Physostigmine caused myoclonus in two patients with Alzheimer’s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.

Original language	English (US)
Pages (from-to)	345-346
Number of pages	2
Journal	Neurology
Volume	37
Issue number	2
DOIs	https://doi.org/10.1212/wnl.37.2.345
State	Published - Feb 1987
Externally published	Yes

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/wnl.37.2.345

Cite this

@article{8b5596fed1194bf09cd6737b2c296ece,

title = "Physostigmine-induced myoclonus in Alzheimer{\textquoteright}s disease",

abstract = "Physostigmine caused myoclonus in two patients with Alzheimer{\textquoteright}s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.",

author = "Richard Mayeux and Marilyn Albert and Michael Jenike",

year = "1987",

month = feb,

doi = "10.1212/wnl.37.2.345",

language = "English (US)",

volume = "37",

pages = "345--346",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - Physostigmine-induced myoclonus in Alzheimer’s disease

AU - Mayeux, Richard

AU - Albert, Marilyn

AU - Jenike, Michael

PY - 1987/2

Y1 - 1987/2

N2 - Physostigmine caused myoclonus in two patients with Alzheimer’s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.

AB - Physostigmine caused myoclonus in two patients with Alzheimer’s disease during a clinical trial. Neither patient had myoclonus before or after physostigmine treatment. We hypothesize that physostigmine reduced the sensitivity of the remaining muscarinic receptors in these two patients, altering the interaction between cholinergic and either serotoninergic or dopaminergic neurotransmitter systems.

UR - http://www.scopus.com/inward/record.url?scp=0023113132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023113132&partnerID=8YFLogxK

U2 - 10.1212/wnl.37.2.345

DO - 10.1212/wnl.37.2.345

M3 - Article

C2 - 3808321

AN - SCOPUS:0023113132

SN - 0028-3878

VL - 37

SP - 345

EP - 346

JO - Neurology

JF - Neurology

IS - 2

ER -

Physostigmine-induced myoclonus in Alzheimer’s disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this